Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Surmodics, Inc. (NASDAQ: SRDX) is a dynamic player in the healthcare industry, partnering with both established and emerging medical device, diagnostic, and life sciences companies. The company specializes in developing and commercializing innovative products aimed at improving lives through better disease detection and treatment.
Surmodics operates under two main segments: the Medical Device unit and the Vitro Diagnostics unit. The Medical Device unit primarily focuses on performance coatings and surface modification technologies. Recently, Surmodics has expanded its role from being a provider of coating technologies to offering complete product solutions thanks to strategic acquisitions.
In the Vitro Diagnostics unit, Surmodics manufactures chemical and biological components used in a variety of in vitro diagnostic immunoassay and molecular tests, serving the diagnostic and biomedical research markets. This segment plays a crucial role in the healthcare industry by providing essential materials for disease detection and research.
Surmodics' mission is steadfast: to enhance the detection and treatment of diseases by leveraging its technology to address complex challenges in the medical device and diagnostic fields. The company is committed to fostering innovation and advancing healthcare solutions, ensuring they remain at the forefront of the industry.
Recent Achievements:
- Successful integration of acquired companies, enhancing their whole-product solutions capability.
- Development of cutting-edge diagnostic technologies improving the accuracy and efficiency of disease detection.
- Establishment of key partnerships with industry leaders to drive innovation and expand market reach.
Current Projects:
- Advancing their surface modification technologies to meet evolving medical needs.
- Expanding their product portfolio to provide comprehensive solutions in the medical device sector.
- Ongoing research and development to innovate and improve diagnostic components.
Surmodics is well-positioned financially, with the majority of its revenue derived from its Medical Device segment. This financial stability supports their ongoing commitment to innovation and excellence in the healthcare industry.
Surmodics, Inc. (NASDAQ:SRDX) has introduced the industry’s first suite of torqueable peripheral microcatheters through its Sublime Radial Access Platform. Dr. Ankur Lodha and Dr. Pradeep Nair were the first physicians to utilize the Sublime™ microcatheter, which is currently in limited market evaluation, with a full launch expected in FY 2024. This new line includes microcatheters designed for superior navigation of complex lesions in both transradial and transfemoral procedures. Notably, these microcatheters boast features like Pristyne™ hydrophilic coating and dual stainless steel locked-braid layers for enhanced torque control. The company’s commitment to expanding its endovascular devices portfolio aims to address unmet clinical needs and improve patient outcomes in peripheral artery disease.
Surmodics, Inc. (Nasdaq: SRDX) has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place from April 17-20, 2023. Management will present on April 20 at 10:15 a.m. ET. Investors can access the live webcast of the presentation via the company’s website under the 'Events & Presentations' section. A replay will be available for 90 days post-event.
Surmodics specializes in performance coating technologies for medical devices and in vitro diagnostic tests, with a focus on developing solutions for unmet clinical needs. Headquartered in Eden Prairie, Minnesota, the company aims to enhance disease detection and treatment through innovative technologies.
Surmodics, Inc. (NASDAQ:SRDX) has received formal feedback from the FDA about its SurVeil™ drug-coated balloon (DCB) application, enabling a streamlined amendment process for its PMA application. The feedback clarifies the necessary requirements, significantly reducing the anticipated time and costs involved. CEO Gary Maharaj expressed optimism regarding the progress, stating that they do not foresee additional biocompatibility studies, allowing for an expected submission in Q3 of fiscal 2023 and aiming for approval in Q4 of the same year. This advancement is crucial for Surmodics’ mission to address unmet clinical needs in treating peripheral artery disease.
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and diagnostic technologies, announced its participation in two upcoming investor conferences. The 33rd Oppenheimer Annual Healthcare Conference will be held virtually from March 13-15, 2023, with Surmodics presenting on March 15 at 10:40 a.m. ET. The Sidoti Small-Cap Conference is scheduled for March 22-23, 2023, featuring 1x1 investor meetings but no formal presentation. Investors can access a live webcast of the presentation through the company's website, with replays available for 90 days.
Surmodics focuses on innovative vascular intervention devices and diagnostic technologies, aiming to enhance disease detection and treatment.
Surmodics (Nasdaq: SRDX) reported Q1 fiscal 2023 results with total revenue of $24.9 million, an 8% increase year-over-year. The GAAP diluted EPS was $(0.56), down from $(0.20) a year prior. Highlights include a 12% revenue jump in the Medical Device segment and a new five-year credit agreement with MidCap Financial. However, the FDA indicated that the SurVeil drug-coated balloon (DCB) PMA application is not currently approvable, prompting a spending reduction plan, including a 13% workforce cut, to save approximately $10-11 million this fiscal year. Updated guidance for fiscal 2023 projects revenue between $102 million and $106 million.
Surmodics, Inc. (NASDAQ: SRDX) will hold its Annual Meeting of Shareholders on
Surmodics, Inc. (Nasdaq: SRDX) will release its first quarter fiscal year 2023 financial results after the market closes on February 6. Following this, a live webcast and conference call will take place at 4:00 p.m. CT to discuss results and achievements, including a Q&A session. Access to the webcast is available on the Company’s website, specifically under the 'Events & Presentations' section. An audio replay will be available post-call until February 20. Surmodics provides advanced medical device technologies and is focused on improving disease detection and treatment.
Surmodics, Inc. (NASDAQ:SRDX) announced the successful 12-month results of its SWING trial for the Sundance™ Sirolimus-Coated Balloon (SCB) at the ISET symposium in Miami. The trial, which included 35 patients, reported no perioperative deaths and only one major re-intervention. Notably, the primary patency rate remained at 80% after a year, demonstrating the efficacy of the company's Crystalline Drug Release (CDR) platform. CDR enhances sirolimus delivery and retention in tissues compared to traditional methods. The SWING trial marks a significant step in advancing medical technology for peripheral artery disease treatment.
Surmodics, Inc. (NASDAQ:SRDX) has received a non-approvable letter from the U.S. Food and Drug Administration regarding its SurVeil™ drug-coated balloon (DCB) premarket approval application. The FDA specified that additional information related to biocompatibility and labeling is required to make the application approvable. However, the FDA did not question the submitted human clinical data. CEO Gary Maharaj expressed disappointment but affirmed confidence in the SurVeil DCB's performance. Surmodics plans to discuss the FDA's feedback with the agency and evaluate options to conserve cash following this development.
Surmodics, Inc. (NASDAQ:SRDX) announced the presentation of 12-month data from the SWING Trial, evaluating the safety and performance of its Sundance™ Sirolimus Drug-Coated Balloon (DCB). This first-in-human study will be discussed by Professor Ramon Varcoe on January 18 at the 35th International Symposium on Endovascular Therapy in Miami, Florida.
The Sundance DCB utilizes a microcrystalline sirolimus coating to enhance drug delivery and reduce restenosis. Currently, this product is for investigational use only and not available for sale globally.
FAQ
What is the current stock price of Surmodics (SRDX)?
What is the market cap of Surmodics (SRDX)?
What does Surmodics, Inc. specialize in?
What are the main business segments of Surmodics, Inc.?
What is the mission of Surmodics, Inc.?
Who does Surmodics, Inc. partner with?
Where does Surmodics, Inc. derive the majority of its revenue from?
What recent achievements has Surmodics, Inc. accomplished?
What current projects is Surmodics, Inc. working on?
How is Surmodics, Inc. contributing to the healthcare industry?
What role does the Vitro Diagnostics unit play in Surmodics, Inc.?
How is Surmodics, Inc. positioned financially?
